1 / 16

Chapter 67

Chapter 67. The Immune System and Antiretroviral Medications. Drug Overview. Antiretrovirals Nucleoside reverse transcriptase inhibitors (NRTIs) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Protease inhibitors (PIs) Second-generation PI fusion inhibitor 

oakley
Download Presentation

Chapter 67

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chapter 67 The Immune System and Antiretroviral Medications

  2. Drug Overview • Antiretrovirals • Nucleoside reverse transcriptase inhibitors (NRTIs) • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) • Protease inhibitors (PIs) • Second-generation PI fusion inhibitor  • HIV integrase inhibitors

  3. Drug Overview • Indications • Nucleoside reverse transcriptase inhibitors (NRTIs) • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) • Protease inhibitors (PIs) • Second-generation PI fusion inhibitor  • HIV integrase inhibitors

  4. Mechanism of Action • Highly Active Antiretroviral Treatment (HAART) • Reverse Transcriptase Inhibitors • Protease Inhibitors • Fusion Inhibitors • HIV Integrase Inhibitors

  5. Treatment Principles • Standardized Guidelines • Guidelines from the International AIDS Society–USA • Hammer SM et al: International AIDS Society–USA Panel: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA Panel, JAMA 296:827-843, 2006

  6. Treatment Principles • Evidence-Based Recommendations • Beneficial • Unknown effectiveness • Cardinal Points of Treatment • Initiation of therapy in symptomatic persons • Initiation of therapy in asymptomatic persons • Antiretroviral choice • Special populations • Adherence

  7. Treatment Principles • Cardinal Points of Treatment (cont’d) • Prophylaxis and prevention • How to Monitor • Patient Variables • Special populations • Geriatrics • Pediatrics • Pregnancy and lactation

  8. Treatment Principles • Patient Education

  9. Reverse Transcriptase Inhibitors • zidovudine (ZDV, AZT) (Retrovir) • Contraindications • Warnings • Precautions • Adverse effects • Drug interactions • Dosage and administration

  10. Reverse Transcriptase Inhibitors • Other Drugs in Class • lamivudine (3TC) (Epivir) • Contraindications • Warnings • Important differences among lamivudine-containing products • Precautions • Adverse effects • Drug interactions • Dosage and administration

  11. Reverse Transcriptase Inhibitors • Other Drugs in Class (cont’d) • abacavir (Ziagen) • Adverse effects • Dosage and administration

  12. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) • delavirdine mesylate (DLV) (Rescriptor) • Contraindications • Precautions • Drug interactions • Other Drugs in Class • Similar to the prototype except: • efavirenz (Sustiva) • Precautions • Drug interactions • Adverse effects • nevirapine (Viramune) • Adverse effects

  13. Protease Inhibitors • ritonavir (Norvir) • Contraindications • Warnings • Precautions • Drug interactions • Dosage and administration

  14. Fusion Inhibitor • enfuvirtide (Fuzeon, T-20) • Contraindications • Warnings

  15. HIV Integrase Inhibitors • raltegravir (Isentress) • Indications • Adverse effects • Dosage and administration

  16. Combination Drug Therapies • See Table 67-4

More Related